The Drug-Induced Respiratory Disease Website and App

Frequency - Incidence

Incidence of respiratory adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases

Evidence level/grade

Evidence level for respiratory adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic

V.b

Eosinophilic pleural effusion

Publications

Alagha K, Tummino C, Sofalvi T, Chanez P

Iatrogenic eosinophilic pleural effusion.

European respiratory review : an official journal of the European Respiratory Society. 2011;20(120):118-20

Lê-Quang B, Calmels P, Valayer-Chaléat E, Fayolle-Minon I, Gautheron V

Dantrolene and pleural effusion: case report and review of literature.

Spinal cord. 2004;42(5):317-20

Felz MW, Haviland-Foley DJ

Eosinophilic pleural effusion due to dantrolene: resolution with steroid therapy.

Southern medical journal. 2001;94(5):502-4

Dohen F, Montagne V, Lelieur E

[Dantrolene-induced pleurisy: a case report].

Revue de pneumologie clinique. 2000;56(4):261-3

Mahoney JM, Bachtel MD

Pleural effusion associated with chronic dantrolene administration.

The Annals of pharmacotherapy. 1994;28(5):587-9

Miller DH, Haas LF

Pneumonitis, pleural effusion and pericarditis following treatment with dantrolene.

Journal of neurology, neurosurgery, and psychiatry. 1984;47(5):553-4

Petusevsky ML, Faling LJ, Rocklin RE, Snider GL, Merliss AD, Moses JM, Dorman SA

Pleuropericardial reaction to treatment with dantrolene.

JAMA. 1979;242(25):2772-4